WuXi Biologics (Cayman) Inc. (2269.HK) HKSE
35.14
+0.52(+1.50%)
Currency In HKD
- General
- Statistics
- Historical Data
- Profile
- Financials
35.14
+0.52(+1.50%)
Currency In HKD
Address
No. 108, Meiliang Road
Wuxi, 214092
China
Phone
86 51081831205
Sector
Healthcare
Industry
Biotechnology
Employees
12575
First IPO Date
June 13, 2017
| Name | Title | Pay | Year Born |
| Zhisheng Chen | Chief Executive Officer & Executive Director | 18.99M | 1973 |
| Jian Dong | Chief Executive Officer of WuXi Vaccines | 0 | 1964 |
| Xuejun Gu | Chief Technology Officer, Executive Vice President of Global Biologics Development Department & Executive Director | 6.15M | 1971 |
| Lihua Yu | Chief Operating Officer & Senior Vice President | 0 | N/A |
| Jijie Gu | Chief Scientific Officer & President of Global Biologics Research | 0 | 1966 |
| Juergen Hinderer | Senior Vice President & Head of Global Engineering | 0 | 1965 |
| He Wang | General Counsel, Chief Compliance Officer, SVP and Head of Legal & Compliance Department | 0 | N/A |
| Angus Scott Marshall Turner | Senior Vice President and Head of Global BD & Alliance Management | 0 | 1968 |
| Ming Tu | Chief Financial Officer & Executive Vice President | 0 | 1969 |
| William Aitchison | Senior Vice President and Head of US Operations & Key Account Executive Advisor | 0 | 1955 |
| Lina Fan | Senior Vice President & Head of Investor Relations | 0 | N/A |
| Li Xiong | Vice President & Head of Global Human Resources | 0 | N/A |
| Xiaohui Liu | Executive VP & Chief Human Resources Officer | 0 | N/A |
| Ge Li | Founder & Chairman | 0 | 1967 |
WuXi Biologics (Cayman) Inc. provides end-to-end solutions and services for biologics discovery, development and manufacturing in the People's Republic of China, North America, Europe, and internationally. The company also engages in the provision of consultation services in relation to the biopharmaceutical technology, international sales contracting services, testing and development of testing technologies, sales and marketing services, and biologics clinical and manufacturing services; production and sale of medicals; vaccine CDMO and related business; and material supplier activities. WuXi Biologics (Cayman) Inc. has strategic partnership with ImmuneOncia Therapeutics, Legochem Biosciences Inc, Worg Pharma, OncoC4, and Exelixis Inc. The company was incorporated in 2014 and is headquartered in Wuxi, China.